COVID-19 vaccine defends monkeys from a new coronavirus

Scientists all over the world are working on a vaccine to prevent coronavirus, and for the first time the monkey experiments conducted in a Chinese laboratory have been successful.

According to data from a Chinese pharmaceutical company, animal experiments with the Novel Corona virus vaccine revealed that the vaccine largely protects monkeys from infection and was first developed in a Chinese laboratory. Monkey vaccine trials were successful.
A report published in the scientific journal Science claims that a drug company reported that it had injected two different doses of vaccine into eight monkeys belonging to a species not at risk of extinction.

COVID-19 vaccine defends monkeys from a new coronavirus

There are no side effects for this vaccine, experiments with these monkeys have proven successful. The vaccine is similar to old medicine, which was developed by incorporating chemically inactivated viruses.
The company said in a statement that all monkeys are largely immune to infection.
According to the evaluation of the company, the four monkeys received high doses of the vaccine and did not show any symptoms in the lungs until seven days after the virus entered their bodies.
The company said the remaining four monkeys, who received low doses of the vaccine, were positive for the virus after injecting it, but it recovered automatically. In contrast, the four monkeys that were not vaccinated were seriously ill with the virus and the development of pneumonia.
Monkeys who got the largest dosage of the vaccine gave the greatest response: seven days after the virus was acquired by the animals, the researchers were unable to find it in the pharynx or lungs. In an April 19 post on the bioRxiv preprint site, the Sinovac team confirmed that certain low-dose animals had a "virus" but also seemed to have regulated the infection. Four species, on the other side, developed elevated amounts of viral RNA in various areas of the body and acute pneumonia. Results "owe us a lot of faith" that the vaccine should operate on people, says Meng Wenning, Senior Manager of Abroad Regulatory Affairs at Sinovac.
However, Douglas Reed of the University of Pittsburgh, who discovers and measures COVID-19 vaccines in monkey trials, claims that the number of species are too limited to yield statistically meaningful effects. His team also has a paper in preparation that poses questions regarding whether the Sinovac team is that the stock of modern coronaviruses used to target animals: it could have triggered a shift in that make them less descriptive than they are in humans.

Post a comment